Scarica l'app Stockscreener
6.75
2.90%
0.19
Dopo l'orario di chiusura:
6.75
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Diamedica Therapeutics Inc Borsa (DMAC) Ultime notizie
Price to earnings forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
(DMAC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
DiaMedica Therapeutics Inc. (DMAC) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
DiaMedica Therapeutics Inc. (DMAC) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Four New York investor talks are planned for September by DiaMedica - Stock Titan
Understanding the Setup: (DMAC) and Scalable Risk - Stock Traders Daily
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet - Yahoo Finance
DiaMedica Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
DiaMedica (DMAC) Results Versus Estimates: EPS Lands Above Forecast; Share Response: The Market Price Advances 1.82% in the Current UpdateManagement Tone Analysis - vinanet.vn
DiaMedica Therapeutics Inc (DMAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
META_TITLE_QUOTE - Yahoo Finance
DiaMedica's DM199: Multiple Catalysts AheadWill It Deliver? - RTTNews
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript - AOL.com
DMAC Q2 2026 Earnings: Narrower-Than-Expected Loss Reflects Disciplined SpendingEBITDA Estimate Trend - Vinanet
DiaMedica Therapeutics (DMAC) Slips 1.04% as Shares Consolidate Between $6.35 Support and $7.01 ResistanceBPI Bear Correction - vinanet.vn
DiaMedica Therapeutics (DMAC) Edges Lower as Shares Consolidate Within Established RangeWatchlist Stock Ideas - vinanet.vn
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy - Yahoo Finance
What is HC Wainwright's Estimate for DMAC Q3 Earnings? - MarketBeat
DiaMedica Therapeutics Inc. (DMAC) stock price, news, quote and history - Yahoo Finance UK
DiaMedica Therapeutics (DMAC) CEO receives 60,200 RSU award vesting over four years - Stock Titan
DiaMedica Therapeutics CEO John Dietrich Pauls Awarded 60,200 Restricted Stock Units on August 10, 2026 - Kalkine Media
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ... - Yahoo Finance
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highli - GuruFocus
DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration - TipRanks
DiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
DiaMedica Therapeutics (DMAC) Advances Clinical Trials Amid High Price-to-Sales Valuation - GuruFocus
DiaMedica Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
DMAC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - MarketBeat
DiaMedica Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: DiaMedica Q2 2026 loss matches forecast as trials advance - Investing.com
DiaMedica Therapeutics Reports Q2 2026 Form 10-Q Highlighting Clinical Trial Enrollment Challenges - Kalkine Media
DiaMedica Advances Key Phase 2 Programs and Extends Cash Runway Through 2027 - TipRanks
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - BioSpace
DiaMedica Therapeutics (DMAC) Reports Positive Interim Data, Mar - GuruFocus
DiaMedica Q2 net loss widens to $10.1M as DM199 shows clinical promise - scanx.trade
DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results - MarketBeat
DiaMedica Therapeutics reports Q2 net loss $10.1M, cash $43.5M; advances DM199 clinical programs - TradingView
DiaMedica reports $10.1 million Q2 loss as DM199 trials advance - Quiver Quantitative
DiaMedica Therapeutics (NASDAQ: DMAC) increases R&D spend and loss in Q2 2026 - Stock Titan
DiaMedica Therapeutics (DMAC) Slips to $6.75 as Biotech Stock Consolidates Between Key Support and ResistanceSymmetrical Triangle - vinanet.vn
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
DiaMedica Therapeutics Inc (DMAC) Stock News Today - TradingKey
(DMAC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Press Release: DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights - 富途牛牛
DiaMedica Therapeutics Inc (DMAC) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
DiaMedica Therapeutics (DMAC) Climbs 2.91% to $6.73: Key Levels and What to WatchSector Leader Stocks - vinanet.vn
Press Release: DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Moomoo
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Business Wire
DiaMedica Therapeutics (DMAC) Expected to Post Earnings on Tuesday - MarketBeat
1 Main Capital Highlights DiaMedica Therapeutics in Q2 2026 Letter - sekbernews.id
DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential - Yahoo Finance
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 1.5%Should You Sell? - MarketBeat
DMAC|DiaMedica Therapeutics Inc|Price:6.720|Chg%:-0.015 - TradingKey
DiaMedica Therapeutics Inc. Revenue Breakdown – NASDAQ:DMAC - TradingView
DiaMedica Therapeutics Inc (DMAC) Income Statement - TradingKey
DiaMedica Therapeutics Inc (DMAC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
DiaMedica Therapeutics Inc (DMAC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DiaMedica Therapeutics Market Sentiment - Benzinga España
DiaMedica Therapeutics Inc (DMAC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
DMAC|DiaMedica Therapeutics Inc|Price:6.850|Chg%:+0.240 - TradingKey
DiaMedica Therapeutics Inc (DMAC) Cash Flow - TradingKey
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):